Personalized cancer vaccine after surgery for solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to take care of yourself (ECOG score 0-1).
- Your doctor expects you to live at least 6 more months.
- You have a solid tumor and are getting treatment before or after surgery, or your cancer has spread but is stable.
- Your cancer has not gotten worse in the last 28 days.
- Your major organs (like kidneys and liver) are working well enough.
- If you could become pregnant, you agree to use effective birth control and not breastfeed during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
This trial tests a personalized cell therapy (tumor polypeptide DC-CTL) for adults with solid tumors such as colorectal, lung, or breast cancer. The goal is to see if infusing your own immune cells trained to attack cancer can help control the disease.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug called toripalimab. The vaccine is designed specifically for your tumor and may help your body's immune system fight cancer better after surgery or standard treatment.
This trial tests a personalized cancer vaccine, alone or with toripalimab (a drug that helps your immune system fight cancer), in people with non-small cell lung cancer (NSCLC) that was removed by surgery. It aims to see if the vaccine is safe and could help prevent the cancer from coming back.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.